The Role of Elevated Liver-Type Fatty Acid-Binding Proteins in Liver Diseases
- 1 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Pharmaceutical Research
- Vol. 38 (1), 89-95
- https://doi.org/10.1007/s11095-021-02998-x
Abstract
Liver-type fatty acid–binding protein (L-FABP) is mainly expressed in the liver as well as the proximal tubular epithelial cells in the kidney. In general, the proteins and enzymes existing within the hepatocytes have the potential to become biomarkers, for instance alanine aminotransferase, which reflects hepatocellular damage. However, due to reduced hepatocellular function in late stage of chronic liver diseases (e.g. cirrhosis), proteins and enzymes relating to hepatocellular damage are not always accurate measures of disease progression. Recently, several publications have demonstrated elevated serum L-FABP levels during the progression of human liver diseases, including hepatocellular carcinoma (HCC), and were a prognostic factor for survival in acute and chronic liver disease patients. However, the study regarding serum L-FABP levels and hepatic L-FABP expression in liver diseases is not sufficient to understand the molecular mechanism of L-FABP during the progression of these disease states. In this review, we focus on the use of serum and/or hepatic L-FABP expression as a biomarker in human liver diseases, including mechanistic potential in HCC.Keywords
This publication has 35 references indexed in Scilit:
- Urinary liver type fatty acid binding protein in diabetic nephropathyClinica Chimica Acta; International Journal of Clinical Chemistry, 2013
- Liver Fatty Acid-binding Protein Is A Diagnostic Marker to Detect Liver Injury Due to Chronic Hepatitis C InfectionArchives of Medical Research, 2013
- Decreased body weight and hepatic steatosis with altered fatty acid ethanolamide metabolism in aged L-Fabp−/− miceJournal of Lipid Research, 2012
- Randomized controlled trial analyzing the effect of 15 or 30 min intermittent Pringle maneuver on hepatocellular damage during liver surgeryJournal of Hepatology, 2010
- Urinary fatty acid-binding protein 1: an early predictive biomarker of kidney injuryAmerican Journal of Physiology-Renal Physiology, 2009
- Angiopoietin‐2 levels in the hepatic vein as a useful predictor of tumor invasiveness and prognosis in human hepatocellular carcinomaJournal of Gastroenterology and Hepatology, 2008
- Renal L-Type Fatty Acid–Binding Protein in Acute Ischemic InjuryJournal of the American Society of Nephrology, 2007
- Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney diseaseMolecular and Cellular Biochemistry, 2006
- Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studiesJournal of Hepatology, 2006
- Liver fatty acid-binding protein: An early and sensitive plasma marker of hepatocellular damage and a reliable predictor of graft viability after liver transplantation from non-heart-beating donorsTransplantation Proceedings, 2005